文献速递淋巴瘤

基于器官功能的临床试验入排标准对弥漫大B细胞淋巴瘤患者的影响:谁被排除在外?

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
PubMed 文献 · J Clin Oncol · 2021-02-02

该研究基于2002-2015年MER队列中1265例接受标准免疫化疗的DLBCL患者,评估前线试验中基于血红蛋白、中性粒细胞绝对计数、血小板、肌酐清除率和胆红素的器官功能标准所排除的患者比例。结果显示9%-24%的患者仅因基线器官功能被排除,且被排除者无事件生存、总生存及24个月无事件生存均显著更差,更多死于淋巴瘤进展而非治疗并发症。

要点

  • 基于器官功能的入排标准可排除高达24%的真实世界DLBCL患者。
  • 被排除患者生存显著更差,主要死于淋巴瘤进展而非治疗毒性。
  • 现有试验标准可能遗漏高危患者,影响结果外推。

核心结论

  • 当前国内外DLBCL前线试验仅因器官功能标准即排除高达24%的真实世界患者,且被排除者预后显著更差,提示试验结果外推受限并可能遗漏高危患者。

研究设计与样本

  • 研究纳入2002至2015年爱荷华大学和梅奥诊所淋巴瘤SPORE的分子流行病学资源(MER)中连续新诊断淋巴瘤患者,本分析包含1265例接受标准免疫化疗的DLBCL患者。
  • 从DLBCL前线试验中识别血红蛋白、中性粒细胞绝对计数、血小板计数、肌酐清除率和胆红素等器官功能参数,用MER提取的实验室值确定被排除患者的百分比。

主要发现

  • 仅基于基线器官功能,9%至24%的MER中接受标准免疫化疗的DLBCL患者被排除。
  • 基于器官功能不合格的患者无事件生存显著更差(风险比1.67-2.16),总生存显著更差(风险比1.87-2.56),24个月无事件生存显著更差(比值比1.71-2.16)。
  • 不合格患者更可能死于淋巴瘤进展而非治疗相关并发症增加。

关键数值与推荐

  • 器官功能排除标准涉及血红蛋白、中性粒细胞绝对计数、血小板计数、肌酐清除率和胆红素,排除比例范围为9%至24%。
  • 不合格组与合格组比较:无事件生存风险比1.67-2.16,总生存风险比1.87-2.56,24个月无事件生存比值比1.71-2.16。

临床怎么用

  • 临床解读DLBCL前线试验结果时需考虑器官功能标准排除的高危患者群体,避免外推偏差。
  • 未来试验设计可参考交互式在线工具估计基于器官功能的排除比例,以优化入组策略并提高试验代表性。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function-based eligibility criteria on this effect and clinical trial exclusion is less well-understood. METHODS: Consecutive patients with newly diagnosed lymphoma were enrolled from 2002 to 2015 into the Molecular Epidemiology Resource (MER) of the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence. The current analysis includes 1,265 patients with DLBCL receiving standard immunochemotherapy. Organ function parameters were identified from criteria for hemoglobin, absolute neutrophil count, platelet count, creatinine clearance, and bilirubin, as reported in frontline DLBCL trials. Abstracted laboratory values from MER were used to determine the percent (%) of patients excluded. Outcomes and cause-of-death analyses comparing ineligible and eligible groups in MER were conducted. An interactive online tool was developed to estimate exclusions based on organ function for future trial design. RESULTS: Between 9% and 24% of MER patients with DLBCL receiving standard immunochemotherapy were excluded on the basis of baseline organ function alone. Ineligible patients based on organ function had significantly inferior event-free survival (hazard ratios, 1.67-2.16), overall survival (hazard ratios, 1.87-2.56), and event-free survival at 24 months (odds ratio, 1.71-2.16). Ineligible patients were more likely to die from lymphoma progression than increased therapy-related complications. CONCLUSION: Current national and international trials exclude up to 24% of patients from participation on the basis of organ function alone. A significant difference in the outcomes, notably lymphoma-related death, suggests issues with generalization and potential exclusion of high-risk patients. These data will help future clinical trial development and meet US Food and Drug Administration and ASCO recommendations to increase trial accrual.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Khurana A, Mwangi R, Nowakowski GS, et al. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? J Clin Oncol. 2021. PMID: 33529046. doi:10.1200/JCO.20.01935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。